A positive opinion from the European Medicines Agency is not an approval, and the distinction matters more than the headline figure. At its September 2026 meeting, the Committee for Medicinal Products for Human Use recommended twelve new medicines for marketing authorisation and backed extensions of indication for eleven products already on the market. The recommendations now travel to the European Commission, which issues the legally binding decision, after which twenty-seven national systems decide separately what they will pay.
The new molecules span the familiar mix of rare disease, oncology and prophylaxis. Novo Nordisk’s Frehemgo, containing denecimig, was recommended for preventing bleeding episodes in people with haemophilia A. It is described as a factor VIIIa mimetic delivered in a pre-filled pen, with dosing offered monthly, fortnightly or weekly. The company’s chief executive, Mike Doustdar, framed the flexibility as a reduction in treatment burden rather than a leap in efficacy, which is an unusually candid way to present a product and probably an accurate one: for a chronic prophylactic therapy, how often a patient has to think about it is a clinical variable in its own right.
Alexion’s Klygefa, containing gefurulimab, received a positive opinion for generalised myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies, a biomarker-defined subgroup rather than the whole patient population. SFL Pharmaceuticals secured two opinions: Gevalka, containing ensartinib, for ALK-positive advanced non-small cell lung cancer, and Sepalna, containing senaparib, as maintenance treatment in certain advanced ovarian cancers. The pattern is consistent with the direction European oncology assessment has taken for a decade, in which the label increasingly describes a molecular signature instead of an organ.
The eleven label extensions are the part of the meeting that tends to go unreported and often reaches more people. Extending an authorised medicine into a new age group, a new line of therapy or an adjacent condition requires no new manufacturing, no new supply chain and no new prescriber familiarity. It is the cheapest route to expanded access that the regulatory system offers, and it arrives without a launch price negotiation attached.
What the September opinions do not resolve is the gap between authorisation and availability. A centralised marketing authorisation is valid across the single market on the day the Commission signs it, but pricing and reimbursement remain national competences, and the interval between authorisation and actual patient access still varies by well over a year across member states. The joint clinical assessment regime under the health technology assessment regulation was meant to compress part of that gap by removing duplicated clinical appraisal, though it leaves the affordability question untouched.
That is the structural point worth holding onto. Europe’s scientific assessment machinery is working at a steady cadence, producing roughly this volume of opinions every month, and the bottleneck has not been the science for some years. It sits downstream, in twenty-seven budget negotiations that the agency in Amsterdam has no authority over and no mandate to accelerate. Twelve recommendations in September is a good month for the regulator. Whether it becomes a good month for patients is decided elsewhere, and later.
